Article
Oncology
Patrick Schoffski, Daniel S. W. Tan, Miguel Martin, Maria Ochoa-de-Olza, John Sarantopoulos, Richard D. Carvajal, Chrisann Kyi, Taito Esaki, Amy Prawira, Wallace Akerley, Filippo De Braud, Rina Hui, Tian Zhang, Ross A. Soo, Michela Maur, Andrew Weickhardt, Jurgen Krauss, Barbara Deschler-Baier, Allen Lau, Tanay S. Samant, Tyler Longmire, Niladri Roy Chowdhury, Catherine A. Sabatos-Peyton, Nidhi Patel, Radha Ramesh, Tiancen Hu, Ana Carion, Daniel Gusenleitner, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L. Kwak, David S. Hong
Summary: This study presents preclinical characterization and phase I data of the LAG-3 inhibitor ieramilimab in patients with advanced/metastatic solid tumors. The results demonstrate that ieramilimab monotherapy and combination treatment with spartalizumab are well tolerated, with modest antitumor activity observed in the combination arm.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Hironobu Minami, Toshihiko Doi, Masanori Toyoda, Yoshinori Imamura, Naomi Kiyota, Ayako Mitsuma, Tomoya Shimokata, Yoichi Naito, Nobuaki Matsubara, Takeshi Tajima, Kota Tokushige, Kae Ishihara, Scott Cameron, Yuichi Ando
Summary: This study confirmed the safety of spartalizumab given at a dose of up to 10 mg/kg every 2 weeks in Japanese patients with cancers, with no dose-limiting toxicities reported. Pharmacokinetics in Japanese patients aligned with those reported in a global dose-escalation study.
Article
Neurosciences
Stefania Merighi, Enrica Battistello, Ilaria Casetta, Daniela Gragnaniello, Tino Emanuele Poloni, Valentina Medici, Alice Cirrincione, Katia Varani, Fabrizio Vincenzi, Pier Andrea Borea, Stefania Gessi
Summary: This study found that AD patients have significantly higher A(2A) receptor density than controls in both the brain and platelets. The values of A(2A) receptor density in platelets seem to correlate with those in the brain, suggesting a potential role for A(2A) receptors as a marker for AD pathology and a target for novel therapies to modify dementia progression.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Article
Oncology
Szu-Chun Yang, Natalia Kunst, Cary P. Gross, Jung-Der Wang, Wu-Chou Su, Shi-Yi Wang
Summary: Based on subgroup and probabilistic analysis, researchers found that first-line N+I or N+I+chemotherapy for metastatic NSCLC patients was not cost-effective from the U.S. health care sector perspective, regardless of PD-L1 expression levels.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Tamara Mirzapoiazova, Gang Xiao, Bolot Mambetsariev, Mohd W. Nasser, Emily Miaou, Sharad S. Singhal, Saumya Srivastava, Isa Mambetsariev, Michael S. Nelson, Arin Nam, Amita Behal, Pranita Atri, Markus Muschen, Francois L. H. Tissot, James Miser, John S. Kovach, Martin Sattler, Surinder K. Batra, Prakash Kulkarni, Ravi Salgia
Summary: The study demonstrated that combining the PP2A inhibitor LB100 with platinum-based chemotherapy resulted in a synergistic antitumor response in SCLC without apparent toxicity. LB100 sensitized SCLC cells to carboplatin uptake while inhibiting glucose uptake and ATP production, and enhanced T cell infiltration and killing of tumor spheroids. These findings highlight the translational potential of targeting PP2A with LB100 in combination with platinum-based chemotherapy and immunotherapy in SCLC.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Oncology
Qi Xiong, Boyu Qin, Lingli Xin, Bo Yang, Qi Song, Yu Wang, Sujie Zhang, Yi Hu
Summary: This study investigated the efficacy and safety of anlotinib with or without immunotherapy in NSCLC patients, finding that the combination therapy may have slightly longer PFS than anlotinib alone, but the difference was not statistically significant. Brain metastasis was identified as an independent predictor of PFS in NSCLC patients receiving anlotinib treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
H. Kievit, M. B. Muntinghe-Wagenaar, L. B. M. Hijmering-Kappelle, B. I. Hiddinga, J. F. Ubbels, R. Wijsman, G. Slingers, R. de Vries, H. J. M. Groen, H. A. M. Kerstjens, A. J. van der Wekken, T. J. N. Hiltermann
Summary: This study evaluates the safety and tolerability of Stereotactic radiotherapy combined with double Immune Checkpoint Inhibition (SICI) in advanced non-small cell lung cancer patients. The combination of SBRT and double immunotherapy is shown to be safe and feasible.
Article
Oncology
Jessika Contreras, Amar Srivastava, Pamela Samson, Todd DeWees, Ramaswamy Govindan, Maria Q. Baggstrom, Daniel Morgensztern, Michael Roach, Shahed N. Badiyan, Jeffrey Bradley, Saiama Waqar, Clifford Robinson
Summary: The study aimed to evaluate the maximum tolerated dose of hypofractionated proton beam radiation therapy with concurrent weekly carboplatin/paclitaxel in patients with stage II-III non-small cell lung cancer. The results showed that the treatment was acutely well tolerated, with high rates of locoregional control and overall survival. Late serious adverse events were noted in some patients outside of the dose-escalation window.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Chemistry, Medicinal
Hibah M. Aldawsari, Sima Singh, Nabil A. Alhakamy, Rana B. Bakhaidar, Abdulrahman A. Halwani, Nagaraja Sreeharsha, Shaimaa M. Badr-Eldin
Summary: Non-small cell lung cancer is a globally prevalent cause of cancer mortality, with low survival rates primarily due to non-targeted therapeutics and increased risk of metastasis. Patients facing chemotherapy near end-of-life often must weigh the potential benefits against serious adverse effects on quality of life. Increasing efficacy and reducing toxicity are crucial in cancer treatment.
Article
Oncology
Benjamin Solomon, Ana Callejo, Jair Bar, Guy Berchem, Lyudmila Bazhenova, Pierre Saintigny, Fanny Wunder, Jacques Raynaud, Nicolas Girard, J. Jack Lee, Raed Sulaiman, Bruce Prouse, Catherine Bresson, Hila Ventura, Shai Magidi, Eitan Rubin, Brandon Young, Amir Onn, Brian Leyland-Jones, Richard L. Schilsky, Vladimir Lazar, Enriqueta Felip, Razelle Kurzrock
Summary: This study assessed a SIMS-based tri-therapy regimen in advanced non-small cell lung cancer. The results showed that 53% of patients achieved clinical benefit with the combination of avelumab, axitinib, and palbociclib, including tumors that had progressed on pembrolizumab.
Article
Biochemistry & Molecular Biology
Chrisna Matthee, Gisella Terre'Blanche, Helena D. Janse van Rensburg, Janine Aucamp, Lesetja J. Legoabe
Summary: Significant progress has been made in the development of high-affinity adenosine A(1) and/or A(2A) receptor antagonists for potential Parkinson's disease treatment, with research showing that heterocycles can replace problematic functional groups without compromising receptor affinity. Compounds tested in the study demonstrated good drug-likeness and low cytotoxicity, with promising dual A(1)/A(2A) affinity exhibited by some compounds like 3c and 8a, suggesting further research into heterocycles as safe and potent adenosine receptor antagonists.
CHEMICAL BIOLOGY & DRUG DESIGN
(2022)
Article
Oncology
Veronika Pelicon, Tanja Cufer, Lea Knez
Summary: This study investigated the real-world outcomes of mono-IT and chemo-IT as first-line treatments for advanced NSCLC patients in a single academic center in the CEE region. The results showed similar effectiveness and safety of mono-IT and chemo-IT to those observed in randomized clinical trials.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing
Summary: The study aimed to evaluate the safety and efficacy of Sabatolimab and spartalizumab in patients with advanced solid tumors. The results showed that the combination of Sabatolimab plus spartalizumab was well tolerated and showed signs of antitumor activity, with the recommended dose for Sabatolimab being 800 mg Q4W, with or without 400 mg spartalizumab Q4W.
CLINICAL CANCER RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Brigida Stanzione, Alessandro Del Conte, Elisa Bertoli, Elisa De Carlo, Alberto Revelant, Michele Spina, Alessandra Bearz
Summary: ROS1 rearrangements occur in a small percentage of NSCLC patients and can be effectively treated with TKI inhibitors. Crizotinib and entrectinib are two approved TKIs for ROS1-positive NSCLC, with entrectinib showing better activity on the CNS. However, resistance mechanisms can develop over time, leading to tumor progression. Newer generation TKIs with greater potency and brain penetration are currently being investigated.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Shenduo Li, Guilherme Sacchi de Camargo Correia, Jing Wang, Rami Manochakian, Yujie Zhao, Yanyan Lou
Summary: Lung cancer is the leading cause of cancer-related deaths globally, with non-small-cell lung cancer (NSCLC) being the most common type. Although targeted therapy has improved survival in NSCLC patients with actionable mutations, therapy resistance and lack of targeted agents for certain oncogenic driver mutations remain challenges. This review summarizes emerging targeted therapies that have been tested in first-in-human clinical trials in the past year.
Article
Cell Biology
Imene Hamaidi, Lin Zhang, Nayoung Kim, Min-Hsuan Wang, Cristina Iclozan, Bin Fang, Min Liu, John M. Koomen, Anders E. Berglund, Sean J. Yoder, Jiqiang Yao, Robert W. Engelman, Ben C. Creelan, Jose R. Conejo-Garcia, Scott J. Antonia, James J. Mule, Sungjune Kim
Article
Oncology
Benjamin C. Creelan, Tammie C. Yeh, Sang-We Kim, Naoyuki Nogami, Dong-Wan Kim, Laura Q. M. Chow, Shintaro Kanda, Rosemary Taylor, Weifeng Tang, Mei Tang, Helen K. Angell, Martine P. Roudier, Marcelo Marotti, Don L. Gibbons
Summary: This study evaluated the safety and efficacy of Durvalumab and gefitinib in combination for TKI-naive patients with advanced EGFRm NSCLC. The results showed that this combination therapy had higher toxicity than using either agent alone, and did not significantly increase progression-free survival compared to historical controls.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Bradford A. Perez, Sungjune Kim, Minhsuan Wang, Ahmad M. Karimi, Chase Powell, Jiannong Li, Thomas J. Dilling, Alberto Chiappori, Kujtim Latifi, Trevor Rose, Austin Lannon, Gretchen MacMillan, James Saller, G. Daniel Grass, Stephen Rosenberg, Jhanelle Gray, Eric Haura, Ben Creelan, Tawee Tanvetyanon, Andreas Saltos, Michael Shafique, Theresa A. Boyle, Michael J. Schell, Jose R. Conejo-Garcia, Scott J. Antonia
Summary: The study investigated the addition of ipilimumab and nivolumab after thoracic radiation therapy for patients with extensive stage small cell lung cancer, showing higher than expected overall survival rates. Increased CD3+CD8+ tumor infiltration was associated with favorable outcomes in terms of progression-free survival and overall survival.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Letter
Oncology
Misty D. Shields, J. Kevin Hicks, Theresa A. Boyle, Eric B. Haura, Benjamin C. Creelan
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Benjamin C. Creelan, Chao Wang, Jamie K. Teer, Eric M. Toloza, Jiqiang Yao, Sungjune Kim, Ana M. Landin, John E. Mullinax, James J. Saller, Andreas N. Saltos, David R. Noyes, Leighann B. Montoya, Wesley Curry, Shari A. Pilon-Thomas, Alberto A. Chiappori, Tawee Tanvetyanon, Frederic J. Kaye, Zachary J. Thompson, Sean J. Yoder, Bin Fang, John M. Koomen, Amod A. Sarnaik, Dung-Tsa Chen, Jose R. Conejo-Garcia, Eric B. Haura, Scott J. Antonia
Summary: Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) in combination with nivolumab showed potential safety and clinical activity in patients with advanced non-small cell lung cancer, indicating a promising new treatment strategy for metastatic lung cancer.
Article
Multidisciplinary Sciences
Dung-Tsa Chen, Wenyaw Chan, Zachary J. Thompson, Ram Thapa, Amer A. Beg, Andreas N. Saltos, Alberto A. Chiappori, Jhanelle E. Gray, Eric B. Haura, Trevor A. Rose, Ben Creelan
Summary: This study identified the presence of lesion heterogeneity in cancer treatment, which is important for RECIST response classification. Evaluating this heterogeneity can aid in personalized treatment strategies and improve the accuracy of RECIST response classification.
Article
Oncology
Aung Naing, Alain P. Algazi, Gerald S. Falchook, Benjamin C. Creelan, John Powderly, Seth Rosen, Minal Barve, Niharika B. Mettu, Pierre L. Triozzi, John Hamm, Gongfu Zhou, Chris Walker, Zhiwan Dong, Manish R. Patel
Summary: This study evaluated the safety and efficacy of the combination therapy of the IDO1 inhibitor epacadostat and the PD-L1 monoclonal antibody durvalumab in patients with advanced solid tumors. The study findings showed that the combination therapy had common adverse events and low objective response rate, and a higher dose of epacadostat was needed for sufficient drug effect.
Article
Oncology
Casey L. Liveringhouse, Kujtim Latifi, Amalin G. Asous, Nghi B. Lam, Stephen A. Rosenberg, Thomas J. Dilling, Gretchen MacMillan, Alberto A. Chiappori, Eric B. Haura, Ben Creelan, Jhanelle E. Gray, Tawee Tanvetyanon, Michael R. Shafique, Andreas N. Saltos, Ashley A. Weiner, Jeffrey Clarke, Christopher R. Kelsey, Sungjune Kim, James J. Caudell, Trevor A. Rose, Jose R. Conejo-Garcia, Jiannong Li, Michael J. Schell, Scott J. Antonia, Bradford A. Perez
Summary: This multi-institution prospective trial was discontinued early due to unacceptable toxicity when using concurrent ipilimumab with chemoradiation therapy for patients with unresectable stage III non-small cell lung cancer. Despite toxicities, the median progression-free survival was 19.2 months, and the overall survival has not reached the median value yet.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Meeting Abstract
Oncology
A. E. Dohm, J. Tang, M. N. Mills, B. A. Perez, T. J. Robinson, B. Creelan, H. H. M. Yu, D. E. Oliver, K. A. Ahmed
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Meeting Abstract
Oncology
A. E. Dohm, J. Tang, M. N. Mills, B. A. Perez, T. J. Robinson, B. Creelan, J. Gray, A. B. Etame, M. Vogelbaum, P. Forsyth, H. H. M. Yu, D. E. Oliver, K. A. Ahmed
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Meeting Abstract
Oncology
C. Liveringhouse, N. B. Lam, S. A. Rosenberg, T. J. Dilling, G. Macmillan, A. Chiappori, E. B. Haura, B. Creelan, J. Gray, T. Tanvetyanon, M. Shafique, A. N. Saltos, A. A. Weiner, C. R. Kelsey, M. Schell, S. J. Antonia, B. A. Perez
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Meeting Abstract
Oncology
Imene Hamaidi, Lin Zhang, Nayoung Kim, Min Hsuan Wang, Cristina Iclozan, Bin Fang, Min Liu, John M. Koomen, Anders E. Berglund, Sean J. Yoder, Jiqiang Yao, Robert W. Engelman, Ben C. Creelan, Jose R. Conejo-Garcia, James J. Mule, Scott J. Antonia, Sungjune Kim